Ayrmid appoints Ideogen as exclusive partner for Omisirge in EMEA
Ayrmid appointed Ideogen as its exclusive partner to launch a managed access program for Omisirge across 55 markets spanning Europe, MENA and CIS, covering both FDA-approved Omisirge indications.